Skip to main content
. 2016 Feb 19;11(2):e0149722. doi: 10.1371/journal.pone.0149722

Fig 3. The effect of antacids use and metastasis sites on progression-free survival (PFS) and overall survival (OS) among patients with epidermal growth factor receptor-mutant non-small-cell lung cancer who were treated using first-line tyrosine kinase inhibitors.

Fig 3

(A) PFS and (B) OS among patients with brain metastases according to antacid use. (C) PFS and (D) OS among patients with bone metastases according to antacid use. (E) PFS and (F) OS among patients with liver metastases according to antacid use. (G) PFS and (H) OS among patients with pleural metastases according to antacid use.